2025-16003Notice

DEA Considers Cambrex High Point's Bid to Manufacture Controlled Substances

Published Date: 8/21/2025

Notice

Summary

Cambrex High Point, Inc. wants to get official approval to make large amounts of certain controlled drugs. This means they’ll be able to produce these substances legally and help supply medicine makers. If approved, it could affect companies relying on these drugs and might speed up production without extra costs right now.

Analyzed Economic Effects

2 provisions identified: 2 benefits, 0 costs, 0 mixed.

Application to Become Bulk Manufacturer

Cambrex High Point, Inc. has applied to be registered as a bulk manufacturer of controlled substances. If the registration is approved, Cambrex would be legally allowed to produce large quantities of certain controlled drugs and could supply medicine manufacturers.

Potential Supply and Production Effects

The notice states that approval could affect companies that rely on these controlled substances and might speed up production without extra costs right now. That could help medicine makers who use those substances in manufacturing.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
8/21/2025

Department and Agencies

Department
Independent Agency
Agency
Justice Department
Drug Enforcement Administration
Source: View HTML
Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in